News & Events - Flavine - fine chemistry - Welcome (2025)

Flavine is embark­ing upon a new pipeline of pro­pri­etary mas­ter files of gener­ic APIs for all mar­kets. We are proud to announce the avail­abil­i­ty of Rux­oli­tinib Phos­phateAPI.

Flavine has part­nered with a reput­ed CDMO to devel­op and man­u­fac­ture Rux­oli­tinib Phos­phate. Flavine can sup­port your fil­ing strat­e­gy by uti­liz­ing our exper­tise of serv­ing the gener­ic indus­try for 45+years.

Rux­oli­tinib Phos­phate is a potent and selec­tive anti­cancer, inhibitor of Janus kinase‑1 and Janus kinase‑2. As a BCS Class I drug, it is a can­di­date for BCS bio-waiv­er in lieu of BEstudy.

In a world where the health­care rev­o­lu­tion is increas­ing­ly trans­form­ing our lives, Flavine is lead­ing the expan­sion of sourc­ing activ­i­ties for its cus­tomers. For more than 45 years, we are thriv­ing to add val­ue to the busi­ness of both sup­pli­ers and cus­tomers by locat­ing and devel­op­ing qual­i­ty man­u­fac­tur­ers and open­ing up new markets.

Flavine is excit­ed to announce our new, state of the art, GMP-com­pli­ant lab­o­ra­to­ry facil­i­ty that offers com­pre­hen­sive ana­lyt­i­cal ser­vices, QC retest, and release test­ing of active phar­ma­ceu­ti­cal ingre­di­ents and fin­ished dosage forms. Com­ple­ment­ing our full-ser­vice QC test­ing, we also pro­vide robust method devel­op­ment, val­i­da­tion, and trans­fer of phar­ma­ceu­ti­cal prod­ucts and raw materials.